The effect of dexamethasone/cell-penetrating peptide nanoparticles on gene delivery for inner ear therapy

Dexamethasone (Dex)-loaded PHEA-g-C18-Arg8 (PCA) nanoparticles (PCA/Dex) were developed for the delivery of genes to determine the synergistic effect of Dex on gene expression. The cationic PCA nanoparticles were self-assembled to create cationic micelles containing an octadecylamine (C18) core with Dex and an arginine 8 (Arg8) peptide shell for electrostatic complexation with nucleic acids (connexin 26 [Cx26] siRNA,green fluorescent protein [GFP] DNA or brain-derived neurotrophic factor [BDNF] pDNA). The PCA/Dex nanoparticles conjugated with Arg8,a cell-penetrating peptide that enhances permeability through a round window membrane in the inner ear for gene delivery,exhibited high uptake efficiency in HEI-OC1 cells. This potential carrier co-delivering Dex and the gene into inner ear cells has a diameter of 120–140 nm and a zeta potential of 20–25 mV. Different types of genes were complexed with the Dex-loaded PCA nanoparticle (PCA/Dex/gene) for gene expression to induce additional anti-inflammatory effects. PCA/Dex showed mildly increased expression of GFP and lower mRNA expression of inflammatory cytokines (IL1b,IL12,and INFr) than did Dex-free PCA nanoparticles and Lipofectamine® reagent in HEI-OC1 cells. In addition,after loading Cx26 siRNA onto the surface of PCA/Dex,Cx26 gene expression was downregulated according to real-time polymerase chain reaction for 24 h,compared with that using Lipofectamine reagent. After loading BDNF DNA into PCA/Dex,increased expression of BDNF was observed for 30 h,and its signaling pathway resulted in an increase in phosphorylation of Akt,observed by Western blotting. Thus,Dex within PCA/Dex/gene nanoparticles created an anti-inflammatory effect and enhanced gene expression.